Literature DB >> 10195726

Diagnostic and prognostic values of CA 19-9 and CEA in periampullary cancers.

S Y Kau1, Y M Shyr, C H Su, C W Wu, W Y Lui.   

Abstract

BACKGROUND: The roles of carcinoembryonic antigen (CEA) and carbohydrate antigen 19-9 (CA 19-9) in periampullary cancers have not been clearly established. Diagnostic and prognostic values of these two tumor markers were clarified in this study. STUDY
DESIGN: Preoperative serum levels of CEA and CA 19-9, and clinicopathologic features were retrospectively reviewed in 143 surgical patients with periampullary cancer from 1989 to 1997.
RESULTS: There were 86 resectable and 57 unresectable periampullary cancers. CA 19-9 demonstrated significantly higher sensitivity in detecting these cancers than CEA. The cancer with unresectable lesion, total bilirubin >7.3 mg/dL, or tumor size >2 cm tended to associate with higher CA 19-9 level. CEA level was significantly higher in the tumor >2 cm, not in the tumor < or =2 cm. CA 19-9 was a significant prognostic factor in both resectable and unresectable periampullary cancers, but CEA was significant only in the resectable group. Multivariate analysis revealed that independent prognostic factors included CA 19-9, resectability, primary tumor, and stage, and CA 19-9 was the most important one.
CONCLUSION: CA 19-9 provided more important diagnostic and prognostic values than CEA in periampullary cancers and was the most important independent prognostic factor for periampullary cancers. This study recommends serum CA 19-9 as an adjunct in detecting periampullary cancers, in evaluating resectability, and in predicting prognosis.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10195726     DOI: 10.1016/s1072-7515(98)00326-3

Source DB:  PubMed          Journal:  J Am Coll Surg        ISSN: 1072-7515            Impact factor:   6.113


  21 in total

1.  Utility of serum CA19-9 in diagnosis of cholangiocarcinoma: in comparison with CEA.

Authors:  Xing-Lei Qin; Zhuo-Ren Wang; Jing-Sen Shi; Min Lu; Lin Wang; Quan-Ru He
Journal:  World J Gastroenterol       Date:  2004-02-01       Impact factor: 5.742

2.  Value of preoperative serum CA 19-9 levels in predicting resectability for pancreatic cancer.

Authors:  Mehmet Kiliç; Erdal Göçmen; Mesut Tez; Tamer Ertan; Mehmet Keskek; Mahmut Koç
Journal:  Can J Surg       Date:  2006-08       Impact factor: 2.089

3.  The Prognostic Impact of the Lymphocyte-to-Monocyte Ratio in Resected Pancreatic Head Adenocarcinoma.

Authors:  Shunsuke Onoe; Atsuyuki Maeda; Yuichi Takayama; Yasuyuki Fukami; Takamasa Takahashi; Masahito Uji; Yuji Kaneoka
Journal:  Med Princ Pract       Date:  2019-05-20       Impact factor: 1.927

4.  Comorbidity negatively influences prognosis in patients with extrahepatic cholangiocarcinoma.

Authors:  Mario Fernández-Ruiz; Juan-Manuel Guerra-Vales; Francisco Colina-Ruizdelgado
Journal:  World J Gastroenterol       Date:  2009-11-14       Impact factor: 5.742

5.  The clinical utility of serum CA 19-9 in the diagnosis, prognosis and management of pancreatic adenocarcinoma: An evidence based appraisal.

Authors:  Umashankar K Ballehaninna; Ronald S Chamberlain
Journal:  J Gastrointest Oncol       Date:  2012-06

6.  Pancreatic cancer serum biomarker PC-594: Diagnostic performance and comparison to CA19-9.

Authors:  Shawn A Ritchie; Bassirou Chitou; Qingan Zheng; Dushmanthi Jayasinghe; Wei Jin; Asuka Mochizuki; Dayan B Goodenowe
Journal:  World J Gastroenterol       Date:  2015-06-07       Impact factor: 5.742

7.  CA 19-9 and survival in advanced and unresectable pancreatic adenocarcinoma and cholangiocarcinoma.

Authors:  Clinton W Ali; Thomas F Kaye; Douglas J A Adamson; Iain S Tait; Francesco M Polignano; Martin S Highley
Journal:  J Gastrointest Cancer       Date:  2007

8.  Prognosis of resected ampullary adenocarcinoma by preoperative serum CA19-9 levels and platelet-lymphocyte ratio.

Authors:  Richard A Smith; Paula Ghaneh; Robert Sutton; Michael Raraty; Fiona Campbell; John P Neoptolemos
Journal:  J Gastrointest Surg       Date:  2008-06-10       Impact factor: 3.452

9.  Prognostic Impact of the Initial Postoperative CA19-9 Level in Patients with Extrahepatic Bile Duct Cancer.

Authors:  Yuichiro Kato; Shinichiro Takahashi; Naoto Gotohda; Masaru Konishi
Journal:  J Gastrointest Surg       Date:  2016-06-01       Impact factor: 3.452

10.  Evaluation of DNA ploidy in relation with established prognostic factors in patients with locally advanced (unresectable) or metastatic pancreatic adenocarcinoma: a retrospective analysis.

Authors:  Nikolas Tsavaris; Nicolaos Kavantzas; Kostantinos Tsigritis; Ioannis D Xynos; Nikitas Papadoniou; Andreas Lazaris; Christos Kosmas; George Agrogiannis; Anna Dokou; Evangelos Felekouras; Efstathios Antoniou; Aris Polyzos; John Sarantonis; Heracles Tsipras; Gavrilos Karatzas; Alexandros Papalambros; Efstratios S Patsouris
Journal:  BMC Cancer       Date:  2009-07-31       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.